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Abstract
Background: The issue of unblinded outcome-assessors and patients has repeatedly been stressed as a flaw in
allegedly double-blind antidepressant trials. Unblinding bias can for example result from a drug‘s marked side
effects. If such unblinding bias is present for a given drug, then it might be expected that the placebos of that drug
are rated significantly less effective than that of other antidepressants.
Methods: To test this hypothesis, the present exploratory analysis conducted a Bayesian network meta-analysis
(NMA) comparing the efficacy of 19 different placebos in placebo-controlled trials provided in the dataset by
Cipriani et al. (Lancet 2018; 391: 1357–66). Primary outcome was efficacy (continuous) estimated on the
standardized mean difference (SMD) scale and defined as the pre-post change on the Hamilton Depression scale
(HAMD-17), on which information was available in N = 258 trials.
Results: Comparative placebo ranking suggested mirtazapine-placebo (SMD -2.0 [− 5.0–1.0 95% CrI]) to be the
most, and amitriptyline- (SMD 1.2 [− 1.6–3.9 95% CrI]) and trazodone- (SMD 2.1 [− 0.9–5.2 95% CrI]) placebos to be
the least effective placebos. Other placebos suggested to be more effective than amitriptyline- and trazodone-
placebos (based on 95% CrIs excluding zero) were citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine,
sertraline, and venlafaxine placebos. These NMA results were corroborated by the observation that the relative
efficacy between drug and placebo was considerably larger for amitriptyline and trazodone than for instance
mirtazapine, duloxetine, and venlafaxine, supported by a small and insignificant correlation between drug-efficacy
and placebo-efficacy (r = − 0.202, p = 0.408).
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: lisa.holper@bli.uzh.ch
1Department of Psychiatry, Psychotherapy, and Psychosomatics, University
Hospital of Psychiatry, University of Zurich, Lenggstrasse 31, 8032 Zurich,
Switzerland
Full list of author information is available at the end of the article
Holper and Hengartner BMC Psychiatry          (2020) 20:437 
https://doi.org/10.1186/s12888-020-02839-y
(Continued from previous page)
Discussion: The present exploratory NMA indicates that distinguishable side effects of older drugs may unblind
outcome-assessors thus resulting in overestimation of the average drug-placebo difference and underrating bias in
placebo-arms, particularly for the older antidepressant drugs amitriptyline and trazodone. If confirmed in
prospective studies, these findings suggest that efficacy rankings for antidepressants are susceptible to bias and
should be considered unreliable or misleading. The analysis is limited by the focus on the single-comparison
placebos (76%, i.e., placebos assessed in two-arm trials), since double-comparison placebos (25%, i.e., placebos
assessed in three-arm trials) are hard to interpret and therefore not included in the present interpretation. Another
limitation is the problem of multiplicity, which was only approximately accounted for in the Bayesian NMA by
modelling treatment effects as exchangeable.
Keywords: Bayesian network meta-analysis, Placebo, Antidepressants, Unblinding, Side-effects
Background
The controversy about the clinical benefits of new-
generation antidepressants for the acute treatment of de-
pression is ongoing and unresolved [1–4]. One major
issue with antidepressant trials is that they exclusively
rely on subjective outcomes, that is, clinician-ratings of
depression symptoms. Almost all antidepressant trials
are at high or unclear risk of bias with respect to alloca-
tion concealment and blinding of outcome-assessors [1],
two important biases known to inflate effect size esti-
mates for subjective outcomes [5, 6].
Although the issue of unblinded outcome-assessors
and patients has repeatedly been stressed for years as a
major flaw in allegedly double-blind psychiatric drug tri-
als [7–9], it is poorly studied because the vast majority
of trials does not assess (or report) unblinding [10].
Nevertheless, some studies have shown that in trials with
older drugs such as tricyclic antidepressants (TCAs),
e.g., amitriptyline, the blind was frequently broken due
to the drugs‘ marked side effects like sedation, drowsi-
ness, dizziness and dry mouth [11]. As early as in 1967,
Leyburn [12] noted in a Lancet article that “most anti-
depressant drugs cause side-effects which are
recognizable by experienced doctors in a significant pro-
portion of patients. Patients who come into the
consulting-room for assessments, perhaps for the sixth
time and rather bored with the whole thing, but with
their mouths so dry that one can hear their tongues
scraping and clicking about in their mouths, are likely to
be taking, say, amitriptyline, rather than the placebo”.
That is, outcome-assessors in trials of older antidepres-
sants were able to detect with high accuracy which trial
participants received the active treatment and which pla-
cebo. This is a serious issue, because unblinding is asso-
ciated with inflated response estimates for depression
treatments [13, 14]. These findings are strongly sup-
ported by randomized trials of TCAs using active place-
bos that also cause anticholinergic side effects. In these
truly blinded trials, the average drug-placebo difference
was much smaller than in TCA trials with inert placebos
[15]. It is thus plausible that TCAs appeared highly ef-
fective because outcome-raters were able to break blind
and hence to correctly guess who was on active treat-
ment and who on inert placebo. The same principle
probably holds for trazodone, which is also an older sed-
ating drug that can cause marked drowsiness and dizzi-
ness [16, 17] and that is poorly tolerated relative to
selective serotonin reuptake inhibitors (SSRIs), sero-
tonin–norepinephrine reuptake inhibitors (SNRIs) and
other atypical new-generation antidepressants like mirta-
zapine and agomelatine [2].
If this assumption of unblinding bias with older (sedat-
ing) antidepressants is true, then we would expect that
the placebos for older drugs are rated significantly less
effective than those for newer antidepressants that are
better tolerated and have less detectable side effects [2,
18]. Naudet and colleagues [19] previously conducted a
meta-analysis that compared the response to different
placebos. The analysis however included a small number
of trials (N = 31) comparing only fluoxetine and venla-
faxine, which did not reveal differences between fluoxet-
ine- and venlafaxine-placebo. In the present analysis, we
expand their work by focussing on all new-generation
antidepressant-placebos in comparison to the placebos
for the older drugs amitriptyline and trazodone. Based
on the rationale detailed above, we hypothesized that
due to unblinding of outcome-assessors the placebos of
the older drugs would be rated less effective than the
placebos of the newer drugs, which are more difficult to
correctly guess due to their more favourable side effect
profile.
Methods
The exploratory analysis was not based on a written
protocol, but followed the findings of Naudet and col-
leagues [19].
Data sources
A total of 308 randomized placebo-controlled trials con-
ducted between 1979 and 2016 (240 published studies,
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68 unpublished studies) were identified. Three hundred
four trials constituted all the placebo-controlled trials
provided in the GRISELDA dataset by Cipriani and col-
leagues [2], and 4 trials were provided by Furukawa and
colleagues [20]. The supplementary appendix provides a
list of a included studies (Additional file 2). Our primary
outcome was efficacy (continuous) estimated on the
standardized mean difference (SMD) scale and defined
as the pre-post change on the Hamilton Depression
scale (HAMD-17) [21], on which information was avail-
able in N = 258 trials. All placebos were inactive place-
bos. A PRISMA flow-chart detailing the study selection
process is given in the supplementary Fig. S1.
Together, the present dataset compared 19 antidepres-
sants; agomelatine (AGO), amitriptyline (AMI), bupropion
(BUP), citalopram (CIT), desvenlafaxine (DES), duloxetine
(DUL), escitalopram (ESC), fluoxetine (FLO), fluvoxamine
(FLU), levomilnacipran (LEV), mirtazapine (MIR), nefazo-
done (NEF), paroxetine (PAR), reboxetine (REB), sertra-
line (SER), trazodone (TRA), venlafaxine (VEN),
vilazodone (VIL), and vortioxetine (VOR). Clomipramine
(CLO) was not included because in the only placebo-
controlled trial available any information about efficacy
was missing. Milnacipran (MIL) was not included because
no placebo-controlled trials were available.
The primary aim of the present analysis was to com-
pare placebo arms. Placebos were therefore renamed ac-
cording to the antidepressants to which they were
compared with, appended by the letter ‘p’ (Fig. 1), fol-
lowing Naudet and colleagues [19]. Placebos that were
compared to a single antidepressant (i.e., single-
comparison placebos assessed in two-arm trials) were
named after the one drug; and placebos that were com-
pared to two antidepressants (i.e., double-comparison
placebos assessed in three-arm trials) were named after
both drugs. For example, placebos compared to amitrip-
tyline (AMI) were named AMIp; and, placebos com-
pared to amitriptyline (AMI) and mirtazapine (MIR)
were named AMIMIRp. There were no four-arm trials
comparing placebo against three different
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Fig. 1 Network graph. Summary of the evidence of the network comparing drugs versus placebos. The thickness of the lines is proportionate to
the number of trials comparing each pair of drugs/placebos, and the size of each node is proportionate to the number of randomized
participants (sample size); see Fig. S2 for details on the original network and Tab. S1 for details on sample sizes. Single-comparison placebos
discussed in the main analysis, i.e., those assessed in two-arm trials, are highlighted (blue)
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antidepressants; any existing four-arm trials merely con-
sidered different dosages and were therefore named ac-
cording to three-arm trials. This resulted in N = 52
different placebos, 19 of which were single-comparison
placebos (N = 193 trials) and 33 were double comparison
placebos (N = 65 trials, supplementary Fig. S2, Tab. S1).
The last placebo in alphabetical order (VENVORp) was
chosen as reference.
Unadjusted Bayesian NMA
Modeling was conducted based on standard Bayesian
random-effects NMA [22], using the JAGS software (ver-
sion 4·3·0) [23]. Simulations were run for 3 chains with an
adaptive phase of 100′000, a burn-in of 100′000, and a
sampling phase of 200′000 iterations, thinned such that
every 10th iteration was retained. Convergence was en-
sured by considering the Brooks–Gelman–Rubin diagnos-
tics [24] with the potential scale reduction factor R ≤ 1.05
accepted as implying convergence [25]. Bayesian model fit
was based on the deviance information criterion (DIC), a
measure of goodness of fit and complexity [25]. Our pri-
mary outcome efficacy (continuous) was estimated on the
standardized mean difference (SMD) scale.
Multiplicity issues were accounted for by using a sym-
metric random-effects NMA model with exchangeable
treatment effects [26], which have been shown to fit well
when there is no obvious placebo or other reference
treatment in the network, as it was the case in the
present analysis.
Trial baselines were assumed to have exchangeable ef-
fects in order to account for disconnected treatments and
placebos [27], which was the case for the drug-placebo
comparisons FLV-FLVp, LEV-LEVp, and NEF-NEFp
resulting from the afore-mentioned renaming of placebos.
Covariate adjusted Bayesian NMA
Covariate adjusted sensitivity analysis was conducted to
test the robustness of the main analysis by adjusting for
the trial-level covariates, study center (multi- versus
single-center), study dosing schedule (flexible versus
fixed dose), study length (range 4–12 weeks), sample
size, study year (continuous covariate), study year (cat-
egorical covariate, before versus after 2000), publication
status (published versus unpublished trials), and spon-
sorship (sponsored versus unsponsored trials). The co-
variate study year was defined as study year of
completion, study year of publication, or year of drug
approval from the FDA (US Food and Drug Administra-
tion), where available in this order [20]; preference was
given to study year of completion, because unpublished
trials, by definition, have no year of publication. The
resulting study year range was 1979–2014. Treatment-
by-covariate and placebo-by-covariate interactions were
assumed to be exchangeable-related drawn from a ran-
dom distribution with common mean (B) and between-
treatment variance (σB) [28]. The supplementary appen-
dix provides details on the methods applied.
Results
The exploratory results presented in the main text focus
on the single-comparison placebos only, since the
double-comparison placebos are hard to interpret due to
the relative influence of two antidepressants (Fig. 1). The
supplementary appendix provides details on all placebos.
In accordance with previous re-analyses of the Cipriani
dataset, all placebos were less effective than antidepres-
sants (95% credible intervals [CrIs] excluding zero) [1, 3,
4], in line with the main results reported by Cipriani and
colleagues [2].
Comparative ranking of the placebos suggested
mirtazapine-placebo (MIRp, SMD -2.0 [− 5.0–1.0 95%
CrI]) to be the most effective placebo, whereas amitrip-
tyline- (AMIp, SMD 1.2 [− 1.6–3.9 95% CrI]) and trazo-
done- (TRAp, SMD 2.1 [− 0.9–5.2 95% CrI]) placebos
were suggested to be the least effective placebos (Fig. 2,
supplementary Fig. S3). In particular, placebos suggested
to be more effective than AMIp (based on 95% CrIs ex-
cluding zero) were citalopram (CITp), duloxetine
(DULp), escitalopram (ESCp), fluoxetine (FLOp), mirta-
zapine (MIRp), and venlafaxine (VENp) placebos; and
placebos suggested to be more effective than TRAp
(based on 95% CrIs excluding zero) were citalopram
(CITp), desvenlafaxine (DESp), duloxetine (DULp), esci-
talopram (ESCp), fluoxetine (FLOp), mirtazapine
(MIRp), and sertraline (SERp) placebos (Fig. 3; supple-
mentary Fig. S4, Tab. S2).
Further, in order to corroborate our hypothesis that due
to unblinding of outcome-assessors the placebos of the
older drugs may be rated less effective than the placebos
of the newer drugs, the correlation between drug-efficacy
and placebo-efficacy was assessed. We observed that the
overall correlation was small and statistically insignificant
(r = − 0.202, p = 0.408). Consistent with our hypothesis,
the differences in relative efficacy between drug and pla-
cebo was considerably larger for AMI/AMIp and TRA/
TRAp (that is, negatively correlated) than for instance for
MIR/MIRp, DUL/DULp, and VEN/VENp (Fig. 4).
Sensitivity analysis revealed that the differences be-
tween AMIp/TRAp and newer-generation antidepres-
sant became weaker but remained largely unaltered after
adjusting for the trial-level covariates study center, dos-
ing schedule, study length, study size, study year (both
adjusting for the continuous and categorical covariate),
publication status, or sponsorship (supplementary Fig.
S5, Tab. S3). Particularly, the difference between MIRp
and AMIp, and all differences with TRAp remained sig-
nificant (95% CrIs excluding zero).
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Discussion
In this secondary exploratory meta-analysis of the
Cipriani dataset we tested whether the placebos of newer
antidepressants were more effective than the placebos of
the older drugs amitriptyline and trazodone. These two
drugs, together with clomipramine, have been shown to
be less well tolerated than the newer-generation antide-
pressants [2, 18]. Based on the unblinding of investiga-
tors documented in various studies [8, 10, 11], we
therefore hypothesized that outcome-assessors in trials
of these older drugs were more frequently unblinded
due the drugs’ marked and observable side effects. By
consequence, we assumed that the unblinded outcome-
assessors would, consciously or unconsciously, underrate
the response to placebos for these older drugs. In line
with our reasoning, we found that the amitriptyline- and
trazodone-placebos were rated less effective than the
placebos of the newer, better tolerated, antidepressants,
such as SSRIs (citalopram, escitalopram, fluoxetine, ser-
traline), SNRIs (duloxetine, desvenlafaxine, venlafaxine),
and in particular the atypical noradrenergic and specific
serotonergic antidepressant (NaSSA) mirtazapine. Be-
cause trial methodology, sample characteristics and the
rate of positive trials have considerably changed over
time [29, 30], we also controlled for important covariates
such as study center, dosing schedule, study length, sam-
ple size, study year, publication status and sponsorship.
Although the inferiority of the amitriptyline-placebo did
not remain significant (95% CrIs including zero, not-
withstanding the fact that it still indicated lower re-
sponse) except in relation to mirtazapine-placebo, the
differences for the trazodone-placebo compared to new-
generation-placebos remained significant (95% CrIs ex-
cluding zero).
Our findings are compatible with the hypothesis that,
due to unblinding, outcome-assessors may have overesti-
mated the average drug-placebo difference for the older
antidepressant drugs amitriptyline and trazodone. Other
studies also support the view that unblinding may drive
exaggerated response ratings for antidepressants relative
to placebo. For instance, Khan and colleagues [14] found
that the average response to depression treatments was
higher when outcome-assessors were unblinded. The
meta-analysis by Moncrieff and colleagues [15] found
that the response to TCAs was poor when compared to
active placebos (d = 0.17). Likewise, a meta-analysis by
Greenberg and colleagues [13] found that the clinician-
rated response to TCAs was small (d = 0.25) in “blinder”
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Fig. 2 Forest plot. Forest plot comparing placebo efficacy estimates on the standardized mean difference (SMD) scale with credible intervals [CrI].
Circle size is proportionate to trial size. The last placebo in alphabetical order (VENVORp) was chosen as reference placebo, which is thus set to
zero in this plot. Placebos are ranked from most to least effective (top to bottom). See Fig. S3 for details on all placebos
Holper and Hengartner BMC Psychiatry          (2020) 20:437 Page 5 of 10
three-arm trials which contained an active-control in
addition to placebo-control. Moreover, in these three-arm
trials the response to the TCAs was close to zero (d =
0.06) when assessed with patient self-reports, suggesting
that outcome-assessors see drug-placebo differences that
the thus rated patients personally do not perceive.
The present findings are important for the interpret-
ation of the comparative response to different antide-
pressants as provided by Cipriani and colleagues [2]. In
their supplement, Cipriani and colleagues [2] reported
that adjusting for the probability of receiving placebo in-
creased the response to amitriptyline from OR = 2.13 to
a striking OR = 3.16 (48% increase). Similarly, for trazo-
done, this resulted in an increase from OR = 1.51 to
OR = 1.97 (30% increase). These findings clearly illus-
trate that the average treatment response for both ami-
triptyline and trazodone increases substantially when
they were compared to placebo in a two-arm trial, pre-
sumably because including a placebo-arm makes it much
easier for outcome-assessors to detect which participants
received the investigational drug than in an active-
controlled trial.
Consistent with our hypothesis that unblinding of
outcome-assessors in trials of older drugs biases the aver-
age drug-placebo difference, a meta-analysis [31] of the
placebo response has shown that the average placebo re-
sponse in 2005 was more than twice larger than the pla-
cebo response in 1980 when assessed by outcome-
assessors. However, no change over time was found for
patient self-ratings [31], which again bolsters our findings
detailed above that outcome-assessors rate drug-placebo
differences differently to what patients personally perceive
[13]. It is also important to stress that while the placebo
response has considerably increased during the 1980s
[32], since about 1991 the average placebo response
remained largely constant around 35–40% when changes
in trial design features are taken into account [20, 33].
We see no reason to assume that there is no unblind-
ing in trials of SSRI, SNRI, or NaSSA antidepressants, al-
though the bias is presumably less pronounced as the
Fig. 3 Pairwise comparisons. Listed are pairwise comparisons between placebos efficacy (standardized mean difference, SMD) with 95% credible
intervals [CrI]. SMD smaller than 0 favor the row-defining placebo, and vice versa, SMD larger than 0 favor the column-defining placebo.
Significant results are bold and underscored. See Fig. S4 and Tab. S2 for details on all placebos
Holper and Hengartner BMC Psychiatry          (2020) 20:437 Page 6 of 10
newer drugs are better tolerated than TCAs [18]. For ex-
ample, mirtazapine, which has a unique dual mode of
action as a noradrenergic and specific serotonergic anti-
depressant [34], has sedating effects due to its affinity to
histamine receptors at low plasma concentrations [35].
This antihistamine effect, however, is offset at higher
doses by increased noradrenergic transmission, which
reduces its sedating effect [36–38]. Mirtazapine is fur-
ther considered to have a lower risk of anticholinergic or
serotonin-related adverse effects often associated with
other antidepressants (such as sexual dysfunction, nau-
sea, etc.), even lower than SSRIs, and may actually im-
prove certain side effects when taken in conjunction
with other antidepressants [39–41].
Nevertheless, new-generation antidepressants also
cause side effects [42], which is why dropout rates due
to adverse events are higher for new-generation antide-
pressants than placebo (but of course still lower than
dropout rates of older antidepressants) [2]. Experienced
clinicians may thus still be able to correctly guess,
whether a participant receives placebo or active treat-
ment. In accordance, in the re-analysis of the Hypericum
Depression Trial, Chen et al. [43] showed that clinicians
were better at correctly guessing placebo than sertraline
or hypericum. In addition, side effects were more
pronounced among participants for which the clinicians
guessed active treatment (which indicates unblinding
due to side effects), and improvements on active treat-
ment relative to placebo were larger when the clinicians
guessed active treatment. We therefore suggest that
unblinding bias is also an issue in trials of newer antide-
pressants, although it is probably less pronounced than
in trials of the poorer tolerated older antidepressants.
Finally, it is important to note that our analysis cannot
fully rule out alternative explanations. For instance, in-
stead of unblinding, another reason could be the trans-
formation of trial protocols over time. To name just one
example, inclusion and exclusion criteria of antidepres-
sant trials have become more restrictive over time,
meaning that trial participants are increasingly unrepre-
sentative [44]. Although controlling for study year cer-
tainly reduces this confounding effect in part, it cannot
remove it altogether. To confirm our hypothesis, a pre-
registered prospective study is required. Given that side
effects that are observable for an outcome assessor even
when not reported by the patient (e.g., dry mouth,
tremor, drowsiness, somnolence) are presumably those
causing unblinding, it would be worthwhile to examine
whether these specific side effects (relative to less detect-
able side effects such as sexual dysfunction and lack of















































Fig. 4 Correlation between drug-efficacy and placebo-efficacy. Scatter plot illustrating the correlation between drug and placebo efficacy on the
standardized mean difference (SMD) scale. Circle size is proportionate to mean trial size (logarithm). Zero indicates no effect compared to the
reference (VENVORp). The Pearson correlation was small and insignificant (r = − 0.202, p = 0.408)
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appetite) lead to correct identification of treatment re-
ceived and whether they are negatively correlated with
depression ratings in the placebo arm.
The main implication of our study is that unblinding
should be systematically assessed and reported in anti-
depressant trials. This would allow to statistically control
for unblinding effects and it would also be possible to
conduct a confirmatory study as detailed above. If our
hypothesis holds, it would imply that inert placebos are
a poor control and thus the use of active placebos
should be reconsidered. Another implication would be
that efficacy rankings based on NMA must be inter-
preted with caution.
Limitations
A limitation of the present analysis is that it was not
based on a written protocol, but merely followed the
findings of Naudet and colleagues [19].
Another limitation inherent in the present data set is
that the placebos can only be interpreted based on their
comparisons with the corresponding antidepressants to
which they are bound in the network. Here, we focused
on the single-comparison placebos, since the double-
comparison placebos are hard to interpret and therefore
only presented in the supplement. It should therefore be
kept in mind that 24% of the trials also including
double-comparisons were not included in the present
interpretation.
Anther limitation concerns the evidence summarized
in this special placebo NMA, in that all comparisons be-
tween placebos rely on indirect evidence only, and not
on a mixture of direct and indirect comparisons as for
most of the antidepressants; though, in mixed treatment
comparisons, a main part of the evidence is also often
based on indirect evidence [45]. The consistency hypoth-
esis, assuming that effects between direct and indirect
comparisons are the same, can therefore not be verified.
Though, it is impossible in this placebo-context to verify
this hypothesis, one cannot be sure of the validity of the
comparisons considering that indirect comparisons may
not be robust and prone to vibration of effects [46].
A methodological limitation is the problem of multi-
plicity in the present NMA. Standard NMA models usu-
ally do not account for multiple comparisons in
estimating relative treatment effects, which might lead to
exaggerated and overconfident statements regarding
relative treatment effects. The present analysis therefore
applied the Bayesian approximation to reduce that prob-
lem described by Efthimiou and White [26], where treat-
ment effects are modelled exchangeable, and hence
estimates are shrunk away from large values.
A more general limitation is that the reliance on the
similarity hypothesis that assumes that all trials are simi-
lar enough to be pooled together. Cipriani et al. [2]
considered this hypothesis to be valid, but still some un-
measured characteristics might have influenced our find-
ings, such as differences between in- and outpatients or
any other surrogate of depression severity at study entry.
Conclusion
Considering clinician-rated symptom change, the present
analysis suggests amitriptyline-placebo and in particular
trazodone-placebo to be less effective than various SSRI-
(citalopram, escitalopram, fluoxetine, sertraline), SNRI-
(duloxetine, desvenlafaxine, venlafaxine), and NaSSA- (mir-
tazapine) placebos. A likely explanation might be that the
distinguishable sedative side effects and poorer tolerability
of amitriptyline and trazodone may have resulted in
unblinding of outcome-assessors and consequently in an
overestimation of the average drug-placebo difference and
an underrating of symptom-change in the placebo-arms.
These findings illustrate that efficacy rankings for antide-
pressants are susceptible to bias and thus may be consid-
ered unreliable or even misleading. Unless proven
otherwise, it may be assumed that the blind is regularly
broken in antidepressant trials when drugs have marked
and distinguishable side effect profiles. However, our ex-
ploratory post-hoc analysis cannot rule out alternative ex-
planations, which is why the influence of side effects on
unblinding should be tested in preregistered confirmatory
studies.
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